Sensitive Serum Markers For Improved Diagnosis, Monitoring And Screening For Early Detection Of Mesothelioma
Funder
National Health and Medical Research Council
Funding Amount
$410,880.00
Summary
The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of individuals per year and its incidence is increasing. Mesothelioma is predicted to cost communities hundreds of billions of dollars in compensation. This disease is unusually difficult to diagnose and tends to be already quite advanced by the time patients present to the doctor with symptoms. Unfortunately, treatment options for the majority of patients are limited and most die within a year of diagnosis. ....The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of individuals per year and its incidence is increasing. Mesothelioma is predicted to cost communities hundreds of billions of dollars in compensation. This disease is unusually difficult to diagnose and tends to be already quite advanced by the time patients present to the doctor with symptoms. Unfortunately, treatment options for the majority of patients are limited and most die within a year of diagnosis. In different forms of cancer, levels of certain proteins in the blood can be measured and have been shown to indicate the presence of tumour and in some cases the extent of tumour. These proteins are collectively known as tumour markers. Tumour markers for ovarian, prostate, breast and other cancers are used by doctors to help with the diagnosis of specific cancers, to monitor the patients response to treatment and to give a valuable early warning of remission or relapse. There is no tumour marker currently used for patients with mesothelioma. We have shown in early studies published in the prestigious journal The Lancet that soluble mesothelin related protein (SMRP) is actually elevated in more than 75% of mesothelioma patients and in less than 2% of patients with other cancer and non-cancer lung diseases. In this current project we plan to extend our studies looking at blood levels of SMRP to see if they will help in the care of patients with mesothelioma. So far we have done most of the work in a particular group of patients, but it is vital that the work be extended to other groups with different types and durations of exposure to asbestos and to different areas of the country. As part of that we need to test how stable the molecule is in blood samples, because if it is not very stable it wont be a very pratical test. We also plan to look at some other markers that have been clinically useful in other forms of cancer and we will try to identify new, novel mesothelioma specific markers. This work has the potential to impact on patient care in many centres of the world.Read moreRead less
Clinical Utility Of A Novel Serum Marker, Serum Mesothelin Family Protein (SMF) In Mesothelioma Patients
Funder
National Health and Medical Research Council
Funding Amount
$323,250.00
Summary
Asbestos fibres can cause a number of cancers, one of the most aggressive and untreatable being mesothelioma. Unfortunately mesothelioma is largely resistant to the main forms of therapy: surgery, chemotherapy and radiation treatment. The average survival from diagnosis is only 8.5 months. It is sometimes difficult to diagnose mesothelioma and additional tests would be useful. Also, a simple screening test may be able to detect the earlier stages of this disease, and allow for early treatment, w ....Asbestos fibres can cause a number of cancers, one of the most aggressive and untreatable being mesothelioma. Unfortunately mesothelioma is largely resistant to the main forms of therapy: surgery, chemotherapy and radiation treatment. The average survival from diagnosis is only 8.5 months. It is sometimes difficult to diagnose mesothelioma and additional tests would be useful. Also, a simple screening test may be able to detect the earlier stages of this disease, and allow for early treatment, would be of widespread value to the community. Markers of cancer can be detected in the blood for a number of cancers e.g. prostate, colon, liver and ovary. No reliable serum marker for the presence of mesothelioma has been described and this study describes work aimed at further evaluating a novel marker that we have been researching in collaboration with a group from Seattle, USA. Mesothelin is a protein made in mesothelial tissue such as mesothelioma. When an individual develops mesothelioma the levels increase in the blood. Also, a proportion of individuals increased levels of this molecule can be detected prior to presentation. This means that it may become a useful screening tool in asbestos-exposed individuals and might be a clinical indicator of the need for further testing and, if early disease is found, early treatments. Given that early treatment of cancer is more effective than late treatment in most clinical situations, this is likely to improve the prognosis for this disease. For this marker to be clinically useful, a careful correlation between its level in the blood and the exact amount of tumour that is present (based on precised computerised tomography x-ray measurements of the tumour) are important. The findings of this study may have widespread implications for patients with mesothelioma and individuals at risk of developing mesothelioma after exposure to asbestos.Read moreRead less
Blood Biomarker Discovery For The Diagnosis Of Alzheimers Disease
Funder
National Health and Medical Research Council
Funding Amount
$292,639.00
Summary
Alzheimer's disease (AD) currently affects approximately 24 million people world wide, with >200,000 people within Australia currently affected, by 2050 an estimated 730,000+ people will be affected. The discovery of blood based biomarkers for AD will enable earlier diagnosis of AD, allowing early preventative treatments to be given. Thus, reduce the rate of disease progression and the cost of care and, gain significant improvement in the quality of life for the patients and their families.
Tubulovillous Adenomas In Colorectal Tumorigenesis
Funder
National Health and Medical Research Council
Funding Amount
$295,983.00
Summary
Bowel cancer is the second most common cancer affecting Australians today, and half of all patients will not survive their disease. Bowel cancer grows from small growths called polyps. In this project, we aim to investigate changes in genes found in a particularly aggressive type of bowel polyp called a tubulovillous adenoma. A better understanding of these gene changes will aid the future development of molecular tests for early detection and therapeutic options for the treatment of cancer.